Navigation Links
Westaim announces 2007 year-end results
Date:2/15/2008

(1,384) (24,021) (14,042) (69,515)

Cash and cash equivalents

at beginning of period 32,377 69,056 45,035 114,550

-------------------------------------------------------------------------

Cash and cash equivalents

at end of period $ 30,993 $ 45,035 $ 30,993 $ 45,035

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash and cash equivalents

is comprised of:

Cash $ 12,537 $ 9,180 $ 12,537 $ 9,180

Cash equivalents 18,456 35,855 18,456 35,855

Supplemental disclosure of

cash flow information:

Non-cash capital asset

additions included in

accounts payable and

accrued liabilities $ 452 $ 508 $ 452 $ 508

-------------------------------------------------------------------------

-------------------------------------------------------------------------


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
2. Westaim reduces ABCP exposure
3. Westaim announces 2007 third quarter results
4. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
5. The Westaim Corporation update on status of short-term investments
6. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
7. China Holdings Announces Starwood Research Institute Initiates Research Coverage
8. Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners, Inc.
9. Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation
10. Nerites Corporation Announces Closing of Series A Funding Round
11. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 2Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 3Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 4Health News:New book presents comprehensive survey of research into the molecular basis of aging 2Health News:BBVA Chairman Francisco González announces the BBVA Frontiers of Knowledge Awards 2Health News:BBVA Chairman Francisco González announces the BBVA Frontiers of Knowledge Awards 3Health News:Fluoridated water for Queensland ... at last 2Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 2Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 3Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 4Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 5Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 6Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 7Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 8
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 1Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 2Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13865 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3
Other Medicine Technology:Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5